Pharmaceutical company Elan has appointed five new members to the company's board of directors.

ELAN had €5.4 billion wiped off its share value yesterday as shareholders saw the value of their investments fall by 68.62%.

Elan today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s pain treatment PRIALT(R).

ELAN submitted its flagship Antegren drug for approval by European regulators as a treatment for Crohn’s disease yesterday, saying tests showed it worked over a 12-month period.

ELAN and Wyeth Pharmaceuticals have been issued seven patents for joint research into the prevention and treatment of Alzheimer’s disease.

The United States Patent and Trademark Office has issued Neuralab Limited, a subsidiary of Elan, seven patents for the companies' joint research on immunotherapeutic approaches to the prevention and treatment of Alzheimer's disease.

Elan Corporation, the long-troubled Irish drugs maker now on the rebound, surged on stock markets today after reporting that its trial drug for treating multiple sclerosis, Antegren, has been fast-tracked for potential approval in the United States.

Irish pharmaceutical firm Elan and partner Biogen announced today that they have submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for the approval of Antegren for the treatment of multiple sclerosis (MS).

Irish pharmaceutical giant Elan aims to launch a new painkiller in the US early next year since reporting positive results from clinical trials of the product.